ArcticZymes Technologies ASA – Invitation to Capital Markets Day 2026 - 6 March 2026, 09:00–12:00 CET - Stockholm, Sweden
ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30).
ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum
Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and reinforces ArcticZymes’ role as a reliable partner in gene therapy workflows.
ArcticZymes Technologies Launches GMP-Grade Nuclease for Next-Generation Viral Vector Manufacturing.
We are pleased to announce the expansion of our GMP product range, with the introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for viral vector manufacturing.
ArcticZymes Technologies ASA Q4 2024 Results & Presentation
Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.
ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers
Tromsø, Norway – December 9, 2024 – ArcticZymes Technologies ASA (OSE: AZT) ArcticZymes introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.